Mounting preclinical and clinical evidences have proved the optimal role of diets (i.e. DASH (Dietary Approaches to Stop Hypertension) diet, Mediterranean diet) on BP control and a causal role of gut microbiota on the pathogenesis of primary hypertension. Dietary changes appeared to reshape gut microbiota and to ameliorate diseases such as Type 2 Diabetes. A hypothesis is thus raised that dietary changes can be a potential approach to ameliorate hypertension via gut microbiome restoration. This pilot study will utilize an innovative natural dietary formulation (patent ID: CN110250417A) derived from Tartary buckwheat(TBW) diet, in comparison with usual care (guideline-based patient education and lifestyle recommendations), to investigate its effect and safety on primary hypertension treatment, and the underlying mechanisms of gut microbiome restoration.
Primary hypertension is a most prevalent cardiovascular diseases, and becomes a severe global public health issue because of the high morbidity and potential risk to other cardiovascular diseases. Several animal studies and diverse patient cohorts reported that the disorder of gut microbiome correlated with hypertension. Based on the investigators' previous work findings of metagenomics analysis, fecal transplantation and metabolomics changes in hypertension and pre-hypertension patients, a casual role of gut microbiome disorder was observed in primary hypertension and raised a hypothesis that gut microbiome restoration can be a potential approach to ameliorate hypertension. Recent studies indicated FMT, prebiotics, probiotics, dietary changes and other methodologies can assist gut microbiome restoration in diseases such as type 2 diabetes. The investigators therefore develop two pilot studies respectively utilizing FMT capsules (Pilot Study I) and innovative dietary changes (Pilot Study II) to explore the methodologies, effect, safety and underlying mechanisms of gut microbiome restoration on hypertension. These pilot studies also present as the clinical translational part of the research project "The Role of Gut Microbiome in the Pathogenesis of Essential Hypertension"(Project ID 81630014, sponsored by National Natural Science Foundation of China). This study is the Pilot Study II: Objective: With reference of DASH diet and Mediterranean diet, this study aims to explore the effect and safety of an innovative natural dietary formulation (deriving from TBW diet) on primary hypertension, and the underlying mechanisms of gut microbiome restoration. Study Design: A multicenter, randomized, open-label, controlled study. Data quality control and statistical analysis: The investigators have invited professional statistic analysts to assist analyzing data and a third party to supervise data quality. Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before patient enrollment are required.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
130
In addition to adherence to a regular diet and standard hypertension care, participants will receive an innovative dietary formulation incorporated into their daily meals and administered orally.
Regular Diet with Usual Care
Beijing Pinggu Hospital
Beijing, Beijing Municipality, China
First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Second Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
Longgang District People's Hospital of Shenzhen
Shenzhen, Guangdong, China
Clinical Medical College&Affiliated Hospital of Chengdu University
Chengdu, Sichuan, China
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, China
First Affiliated Hospital of Chongqing Medical University
Chongqing, China
the People's Hospital of Ji Xian District
Tianjin, China
Change for Office Systolic Blood Pressure (SBP)
Change for Office Systolic Blood Pressure (SBP)
Time frame: From Baseline to the Month 2 (Week 8) follow-up visit
Change for office SBP
Change for office SBP
Time frame: Baseline, Month 1(Week 4), Month 3(Week 12)
Change for Office Diastolic Blood Pressure (DBP)
Change for Office Diastolic Blood Pressure (DBP)
Time frame: Baseline, Month 1(Week 4), Month 2 (Week 8), Month 3 (Week 12)
Change for daytime average SBP via 24-hour Ambulatory BP Monitoring
Change for daytime average SBP via 24-hour Ambulatory BP Monitoring
Time frame: Baseline, Month 1(Week 4), Month 2(Week 8), Month 3(Week 12)
Change for daytime average DBP via 24-hour Ambulatory BP Monitoring
Change for daytime average DBP via 24-hour Ambulatory BP Monitoring
Time frame: Baseline, Month 1(Week 4), Month 2(Week 8), Month 3(Week 12)
Change for nighttime average SBP via 24-hour Ambulatory BP Monitoring
Change for nighttime average SBP via 24-hour Ambulatory BP Monitoring
Time frame: Baseline, Month 1(Week 4), Month 2(Week 8), Month 3(Week 12)
Change for nighttime average DBP via 24-hour Ambulatory BP Monitoring
Change for nighttime average DBP via 24-hour Ambulatory BP Monitoring
Time frame: Baseline, Month 1(Week 4), Month 2(Week 8), Month 3(Week 12)
Number of Participants with Adverse Events (AEs) as a Measure of Safety
Number of Participants with Adverse Events (AEs) as a Measure of Safety
Time frame: All AEs over 3 months
Intestinal Microbiota Composition Pre- and Post-intervention (innovative dietary formulation or usual care) via Metagenomic Analysis
Intestinal Microbiota Composition Pre- and Post-intervention (innovative dietary formulation or usual care) via Metagenomic Analysis
Time frame: Baseline, Month 1(Week 4), Month 2(Week 8), Month 3(Week 12)
Intestinal Microbiota function Pre- and Post-intervention (innovative dietary formulation or usual care) via Metagenomic Analysis
Intestinal Microbiota function Pre- and Post-intervention (innovative dietary formulation or usual care) via Metagenomic Analysis
Time frame: Baseline, Month 1(Week 4), Month 2(Week 8), Month 3(Week 12)
Plasma Metabolite Composition Pre- and Post-intervention (innovative dietary formulation or usual care) via Metabolomic Analysis
Plasma Metabolite Composition Pre- and Post-intervention (innovative dietary formulation or usual care) via Metabolomic Analysis
Time frame: Baseline, Month 1(Week 4), Month 2(Week 8), Month 3(Week 12)
Change for Fasting Blood Glucose Level
Change for Fasting Blood Glucose Level
Time frame: Baseline, Month 2(Week 8)
Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)
Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)
Time frame: Baseline, Month 2(Week 8)
Change for Body Mass Index
Change for Body Mass Index
Time frame: Baseline, Month 2(Week 8)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.